Inducing remission in inflammatory bowel disease.
Around 2-4 in 1,000 people in Northern Europe have ulcerative colitis or Crohn's disease. Both are chronic relapsing inflammatory disorders of the gastrointestinal tract and share several clinical features. However, they are largely distinct in their risk factors, their genetic, immunological, anatomical and histological features, and their response to medical and surgical therapy. Their treatment is usually considered in two phases: the induction of remission in an acute attack, and the long-term maintenance of remission. In 2001, we discussed maintenance treatment in adults. We now discuss the induction of remission, concentrating on newer therapeutic approaches.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000628:therapy; D003424:Crohn Disease / Q000628:therapy; D016572:Cyclosporine / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000069285:Infliximab; D008727:Methotrexate